Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | HMGCR | P04035 | 5/20 | 0.72 |
| ▸ | RXRA | P19793 | 3/20 | 0.72 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529615 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14273685 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL1582433 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14262755 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL2898752 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL10153166 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL1582437 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL2904607 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14273684 | 0.92 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL13257547 | 0.91 | NR4A2 (0.65) | NR4A2PDE4DNR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | NR4A2 3911/4885PDE4D 579/4885NR1I2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.